文献速递自身炎症与 IgG4 相关病

生物制剂治疗斯蒂尔病切换策略的当前证据:一项系统文献综述

Current evidence on switching between biologic therapies for Still's disease: A systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2025-07-18

该系统综述检索2014年以来关于斯蒂尔病生物制剂治疗的文献,纳入7部指南/共识/最佳实践建议和41项临床试验、观察性研究、登记研究或病例系列。白介素-1抑制剂通常为推荐的一线生物制剂,因耐受性不足、应答不充分或治疗失败时推荐换用另一种白介素-1抑制剂或白介素-6抑制剂,肿瘤坏死因子抑制剂和Janus激酶抑制剂建议用于后线治疗。临床文献报告切换生物制剂在达到临床非活动性疾病或缓解、减少激素用量和降低治疗负担方面有获益。

要点

  • 白介素-1抑制剂通常为斯蒂尔病推荐的一线生物制剂。
  • 因耐受性不足、应答不充分或治疗失败时,推荐换用另一种白介素-1抑制剂或白介素-6抑制剂。
  • 肿瘤坏死因子抑制剂和Janus激酶抑制剂建议用于后线治疗。

核心结论

  • 对于未达到治疗目标的斯蒂尔病患者,切换生物制剂可能是一种与临床获益相关的有用策略。
  • 需要专门设计的对照临床试验(或在缺乏此类试验时采用观察性研究)来确定最佳切换策略。

研究设计与样本

  • 系统文献综述,检索2014年以来发表的关于斯蒂尔病生物制剂治疗的文章。
  • 排除病例报告、患者数少于5例的研究及非英语文献。
  • 共纳入48篇出版物,包括7部治疗指南、共识声明或最佳实践建议,以及41篇临床试验、观察性研究、登记研究或病例系列。

主要发现

  • 白介素-1抑制剂通常为推荐的一线生物制剂。
  • 因耐受性不足、应答不充分或治疗失败时,推荐换用另一种白介素-1抑制剂或白介素-6抑制剂。
  • 肿瘤坏死因子抑制剂和Janus激酶抑制剂被建议用于后线治疗。
  • 临床出版物报告切换生物制剂在达到临床非活动性疾病或缓解、减少激素用量和降低治疗负担方面有获益。

关键数值与推荐

  • 因耐受性不足、应答不充分或治疗失败时,推荐换用另一种白介素-1抑制剂或白介素-6抑制剂。
  • 肿瘤坏死因子抑制剂和Janus激酶抑制剂被建议用于后线治疗。

临床怎么用

  • 对于未达到治疗目标的斯蒂尔病患者,切换生物制剂可能是一种与临床获益相关的有用策略。
  • 需要专门设计的对照临床试验(或在缺乏此类试验时采用观察性研究)来确定最佳切换策略。

局限性

  • 需要专门设计的对照临床试验(或在缺乏此类试验时采用观察性研究)来确定最佳切换策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Still's disease (SD) is increasingly being treated with biologic disease-modifying antirheumatic drugs (bDMARDs) according to a treat-to-target approach, with switching between these agents an integral part of this strategy. However, guidance for the clinician on switching between biologic agents in SD is limited. Here we review the evidence in the literature relating to switching between bDMARDs in SD. METHODS: A systematic review was performed for articles published since 2014 which related to the biologic treatment of SD. Case reports and studies with under 5 patients and non-English language publications were excluded. The resulting publications were reviewed for evidence on switching therapies between bDMARDs. RESULTS: A total of 48 publications included for review included seven treatment guidelines, consensus statements, or best practice recommendations, and 41 publications of clinical trials, observational studies, registry studies, or case series. Interleukin (IL)-1 inhibitors are usually the recommended first-line biologics. Switching to another IL-1 inhibitor or an IL-6 inhibitor was recommended in cases of lack of tolerability, inadequate response or treatment failure. Tumour necrosis factor inhibitors and Janus kinase inhibitors were suggested for later lines of therapy. Clinical publications reported benefits of switching between bDMARDs in terms of attaining clinically inactive disease or remission, steroid-sparing effects, and reductions in treatment burden. CONCLUSION: In patients with SD who are not meeting treatment targets, switching between bDMARDs can be a useful strategy associated with clinical benefits. However, specifically designed, controlled clinical trials (or in their absence, observational studies) are needed to determine optimal switching strategies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Dagna L, Feist E, Horneff G, et al. Current evidence on switching between biologic therapies for Still's disease: A systematic literature review. Semin Arthritis Rheum. 2025. PMID: 40738082. doi:10.1016/j.semarthrit.2025.152789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。